Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

17. März 2025 04:09 ET | Quelle: Araris Biotech

Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech

March 17th, 2025Taiho Pharmaceutical Co., Ltd.Araris Biotech AG Taiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris Biotech Taiho Pharmaceutical Co., Ltd....
08. Januar 2025 08:00 ET | Quelle: Araris Biotech

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris' AraLinQ™ technology

Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive an upfront fee and milestone payments...
12. November 2024 08:00 ET | Quelle: Araris Biotech

Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem

First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...
24. September 2024 08:00 ET | Quelle: Araris Biotech

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)

Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...